User profiles for Deenan Pillay

Deenan Pillay

Verified email at africacentre.ac.za
Cited by 35692

[HTML][HTML] Digital technologies in the public-health response to COVID-19

…, MM Stevens, N Keegan, MJ Short, D Pillay… - Nature medicine, 2020 - nature.com
Digital technologies are being harnessed to support the public-health response to COVID-19
worldwide, including population surveillance, case identification, contact tracing and …

[HTML][HTML] 2011 update of the drug resistance mutations in HIV-1

…, HF Günthard, R Paredes, D Pillay… - Topics in antiviral …, 2011 - ncbi.nlm.nih.gov
The development of more recently approved drugs that cannot be tested as monotherapy
precludes assessment of the impact of resistance on antiretroviral activity that is not seriously …

[HTML][HTML] Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

…, D van de Vijver, SY Rhee, TF Liu, D Pillay… - PloS one, 2009 - journals.plos.org
Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance
inform treatment guidelines and provide feedback on the success of HIV-1 treatment and …

[HTML][HTML] Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based …

…, E Sanchez, SM Paraskevopoulou, D Pillay… - The Lancet infectious …, 2021 - thelancet.com
Background Emergence of variants with specific mutations in key epitopes in the spike
protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of …

[HTML][HTML] Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study

…, A Torralbo, L Shallcross, M Noursadeghi, D Pillay… - The Lancet, 2020 - thelancet.com
Background The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19)
pandemic has unknown effects on overall population mortality. Previous models …

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

…, DR Kuritzkes, JW Mellors, D Pillay… - Clinical Infectious …, 2008 - academic.oup.com
Resistance to antiretroviral drugs remains an important limitation to successful human
immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment …

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …

…, A Pozniak, B Clotet, A Phillips, D Pillay… - The Lancet infectious …, 2011 - thelancet.com
Background The effect of transmitted drug resistance (TDR) on first-line combination
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …

[HTML][HTML] Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global …

…, AW Sawyer, RL Hamers, N Ndembi, D Pillay… - The Lancet, 2012 - thelancet.com
Background The emergence and spread of high levels of HIV-1 drug resistance in resource-limited
settings where combination antiretroviral treatment has been scaled up could …

[HTML][HTML] 2017 update of the drug resistance mutations in HIV-1

…, VA Johnson, R Paredes, D Pillay… - Topics in antiviral …, 2016 - ncbi.nlm.nih.gov
The 2017 edition of the IAS–USA drug resistance mutations list updates the figures last
published in November 2015. The mutations listed are those that have been identified by specific …

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

…, D Nair, B Peters, A Phillips, D Pillay… - HIV …, 2008 - pubmed.ncbi.nlm.nih.gov
… 1 , Jane Anderson, Abdel Babiker, Marta Boffito, Gary Brook, Gary Brough, Duncan
Churchill, Ben Cromarty, Satyajit Das, Martin Fisher, Andrew Freedman, Anna Maria Geretti …